The R21 malaria vaccine is about to get cheaper, thanks to a new deal between UNICEF and the Serum Institute of India, the world’s largest vaccine manufacturer, with financial backing from Gavi, the Vaccine Alliance.
Under the agreement, the vaccine’s price will come down to $2.99 from $3.90 per dose.
According to Gavi, the deal was made possible by utilizing funding from the International Finance Facility for Immunisation, or IFFIm, an innovative financial instrument that raises funding for Gavi’s child immunization work through the issuance of vaccine bonds on capital markets.
Printing articles to share with others is a breach of our terms and conditions and copyright policy. Please use the sharing options on the left side of the article. Devex Pro members may share up to 10 articles per month using the Pro share tool ( ).
About the author
Jenny Lei Ravelo@JennyLeiRavelo
Jenny Lei Ravelo is a Devex Senior Reporter based in Manila. She covers global health, with a particular focus on the World Health Organization, and other development and humanitarian aid trends in Asia Pacific. Prior to Devex, she wrote for ABS-CBN, one of the largest broadcasting networks in the Philippines, and was a copy editor for various international scientific journals. She received her journalism degree from the University of Santo Tomas.
